Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Andrew, Lentzsch, Suzanne, Weisel, Katja, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay K., Quach, Hang, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Scott, Emma C., Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Soong, David, Casneuf, Tineke, Chiu, Christopher, Amin, Himal, Qi, Ming, Thiyagarajah, Piruntha, Sasser, A. Kate, Schecter, Jordan M., Mateos, Maria-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269293/
https://www.ncbi.nlm.nih.gov/pubmed/30237264
http://dx.doi.org/10.3324/haematol.2018.194118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269293/
https://www.ncbi.nlm.nih.gov/pubmed/30237264
http://dx.doi.org/10.3324/haematol.2018.194118

Ejemplares similares